← Eichor
Condition: Overweight Or Obese Type 2 Diabetes Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Overweight Or Obese Type 2 Diabetes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Ad
Phase 2 · 2 location(s) · Golo · NCT05844644A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Phase 3 · 173 location(s) · Eli Lilly and Company · NCT07392190SnapDandCGMinType2Diabetes
NA · 1 location(s) · Ramathibodi Hospital · NCT07533604A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Phase 3 · 25 location(s) · Pfizer · NCT07595549A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without T
Phase 3 · 164 location(s) · Hoffmann-La Roche · NCT07351045Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
Phase 1 · 2 location(s) · Alveus Therapeutics, Inc. · NCT07399678The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal Gastroplication
NA · 1 location(s) · The Society of Bariatric and Metabolic Surgeons of Kazakhsta · NCT07495020A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overw
Phase 2 · 42 location(s) · Eli Lilly and Company · NCT07215559A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type
Phase 3 · 163 location(s) · Hoffmann-La Roche · NCT07351058A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Phase 1/Phase 2 · 1 location(s) · Pfizer · NCT06924320A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Livi
Phase 2 · 147 location(s) · Novo Nordisk A/S · NCT06717698Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Phase 1 · 4 location(s) · OrsoBio, Inc · NCT05822544A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Phase 4 · 21 location(s) · Eli Lilly and Company · NCT07438444Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
NA · 1 location(s) · Kazakh Academy of Nutrition · NCT07728669A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Phase 3 · 162 location(s) · Eli Lilly and Company · NCT07321886A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabet
Phase 3 · 12 location(s) · Hoffmann-La Roche · NCT07670416A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participant
Phase 2 · 40 location(s) · Eli Lilly and Company · NCT07589608Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With We
Phase 3 · 1 location(s) · Hudson Biotech · NCT07481747Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
NA · 1 location(s) · Chinese University of Hong Kong · NCT03875625A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3 · 159 location(s) · Eli Lilly and Company · NCT07282600A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or
Phase 3 · 321 location(s) · AstraZeneca · NCT07667803Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Ob
NA · 4 location(s) · University Hospital, Lille · NCT03821636A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirze
Phase 2 · 60 location(s) · Eli Lilly and Company · NCT06897475Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
Phase N/A · 1 location(s) · Osaka Metropolitan University · NCT06694012A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe
Phase 3 · 303 location(s) · Novo Nordisk A/S · NCT07564414AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type
Phase 3 · 74 location(s) · Novo Nordisk A/S · NCT07533175Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Phase 3 · 1 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07279194A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants
Phase 2 · 8 location(s) · Antag Therapeutics · NCT07724340Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity
Phase N/A · 1 location(s) · Azienda Ospedaliero-Universitaria Consorziale Policlinico di · NCT05908812Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Phase 2 · 21 location(s) · Sun Pharmaceutical Industries Limited · NCT07282743
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.